JENNIFER WARGO to Neoplasms
This is a "connection" page, showing publications JENNIFER WARGO has written about Neoplasms.
Connection Strength
3.174
-
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer. 2024 Jun 19; 12(6).
Score: 0.149
-
Using gut microorganisms to treat cancer. Nat Med. 2023 08; 29(8):1910-1911.
Score: 0.140
-
More fuel for the fire: Gut microbes and toxicity to immune agonist antibodies in cancer. Cell Rep Med. 2021 12 21; 2(12):100482.
Score: 0.126
-
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. Cancer Immunol Res. 2021 04; 9(4):365-370.
Score: 0.119
-
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep. 2020 06 24; 22(7):74.
Score: 0.113
-
Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 03; 65(3):885-896.
Score: 0.111
-
AI finds microbial signatures in tumours and blood across cancer types. Nature. 2020 03; 579(7800):502-503.
Score: 0.111
-
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer. 2020 03; 6(3):192-204.
Score: 0.110
-
The Microbiome in Immuno-oncology. Adv Exp Med Biol. 2020; 1244:325-334.
Score: 0.110
-
The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am. 2019 07; 28(3):369-386.
Score: 0.106
-
The cancer microbiome. Nat Rev Cancer. 2019 07; 19(7):371-376.
Score: 0.105
-
The microbiome, cancer, and cancer therapy. Nat Med. 2019 03; 25(3):377-388.
Score: 0.103
-
Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019 02; 20(2):e77-e91.
Score: 0.103
-
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol. 2018 11; 39(11):900-920.
Score: 0.101
-
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Front Immunol. 2018; 9:946.
Score: 0.098
-
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell. 2018 04 09; 33(4):570-580.
Score: 0.097
-
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol. 2018 Jul; 25(7):1814-1827.
Score: 0.096
-
Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017 Jun 27; 117(1):1-7.
Score: 0.091
-
Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper? Clin Cancer Res. 2017 Jan 15; 23(2):327-329.
Score: 0.088
-
Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep. 2016 07; 18(7):42.
Score: 0.086
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.086
-
Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol. 2016 08; 41:23-31.
Score: 0.085
-
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol. 2015 Aug; 42(4):601-16.
Score: 0.080
-
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 2014 Dec; 4(12):1377-86.
Score: 0.077
-
Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
Score: 0.038
-
Embracing cancer complexity: Hallmarks of systemic disease. Cell. 2024 Mar 28; 187(7):1589-1616.
Score: 0.037
-
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature. 2023 Aug; 620(7974):651-659.
Score: 0.035
-
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol. 2023 09; 20(9):583-603.
Score: 0.035
-
Microbiome influencers of checkpoint blockade-associated toxicity. J Exp Med. 2023 03 06; 220(3).
Score: 0.034
-
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
Score: 0.033
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.032
-
Targeting the gut and tumor microbiota in cancer. Nat Med. 2022 04; 28(4):690-703.
Score: 0.032
-
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 10 14; 184(21):5309-5337.
Score: 0.031
-
The microbiome and human cancer. Science. 2021 03 26; 371(6536).
Score: 0.030
-
Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021 01; 16(1):6-15.
Score: 0.029
-
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020 09; 20(9):522-528.
Score: 0.028
-
The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 05 29; 368(6494):973-980.
Score: 0.028
-
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019 11 05; 116(45):22699-22709.
Score: 0.027
-
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243.
Score: 0.027
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470.
Score: 0.026
-
The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018 06; 15(6):382-396.
Score: 0.025
-
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017 11 03; 15(1):223.
Score: 0.024
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.022
-
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 02 09; 168(4):707-723.
Score: 0.022
-
Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J. 2016 Mar-Apr; 22(2):138-46.
Score: 0.021
-
Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res. 2014 Aug; 2(8):714-9.
Score: 0.019
-
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother. 2009 Mar; 58(3):383-94.
Score: 0.012
-
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
Score: 0.008
-
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
Score: 0.007
-
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861.
Score: 0.007
-
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019 Sep; 46(9):627-636.
Score: 0.007
-
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
Score: 0.006